Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data

GENFIT news: financial news, earnings, stock moves and analysts

Live news related to GENFIT stock (FR0004163111): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.

The latest financial news on GENFIT mainly cover earnings publications, analyst notes et share price moves. The stock trades at €9,54 on Euronext Paris, down 9,49% at the last update. This page lists the articles published on GENFIT stock to track the share price, company announcements and any item likely to influence market perception.

Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
GENFIT
FR0004163111
Pharmaceuticals & Biotechnology / Biotechnology
9,54 € -9,49 %
High10,30 €
Low9,54 €
Last update : 20/11/2026 - 17:35:07 – Euronext Paris – 15 min delay.
Market closed

Latest GENFIT stock news

The Lille-based biotech specialising in liver and metabolic diseases is retreating at midday, in a very poorly oriented Paris session. The move comes …

The Lille-based biotech specialising in liver and metabolic diseases recovers mid-session in a Paris market trending higher. After a decline the previ…

The Lille-based biotech specialising in liver and metabolic diseases recovers at the close, in a Paris market trending lower. It ranks among the index…

The Lille-based biotech specializing in liver and metabolic diseases is losing ground in mid-morning trading, in a Paris market that is clearly trendi…

The Lille-based biotech specializing in liver and metabolic diseases extends its rebound mid-session, in a well-oriented Paris market. The move follow…

The Lille-based biotech specializing in liver and metabolic diseases edges lower late in the afternoon, while the Paris market posts a clear gain. The…

The Lille-based biotech specializing in liver and metabolic diseases is recovering mid-session in a well-oriented Parisian market. The move follows a …

On November 8, 2026, in Denver at the AASLD The Liver Meeting congress, Genfit presented a detailed review of Nangibotide, its lead drug candidate in …

The Lille-based biotech specialising in liver and metabolic diseases collapses mid-session, following a publication whose figures lend themselves to t…

Genfit published its third-quarter financial results on November 5, 2026, which show two movements in opposite directions.Over the first nine months, …

Ad
Chaque matin
Les signaux techniques du marché,
avant l'ouverture.
CAC 40 · SBF 120 · Signaux · Analystes
🤖
Édition du jour — avant bourse
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Signaux haussiers
+5,2%
+1,8%
+0,9%
📉 Signaux baissiers
-14%
-5,7%
🔄 Avis analystes
▲ 35 €
▼ 80 €
Inscrivez-vous pour tout voir →
Avant 9h chaque matin
Données Euronext
Analyse automatique IA